The structural basis for imatinib resistance in chronic myeloid leukaemia (CML) involves the emergence of imatinib-resistant BCR-ABL point mutations; mutations are usually those that impair drug ...

Single-point mutations within the kinase domain of BCR–ABL constitute the most frequent cause of acquired resistance to ABL kinase inhibitors in patients with chronic myeloid leukaemia (CML ...